Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs CG 200745 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors CrystalGenomics
- 09 Nov 2015 Status changed from recruiting to active, no longer recruiting as per Results presented at the 2013 European Cancer Congress
- 28 Dec 2012 Planned number of patients changed from 24 to 36 as reported by ClinicalTrials.gov.
- 09 Oct 2012 Planned End Date changed from 1 Jun 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.